Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,438

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Côté, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,424

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767

Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

Kuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.460 · Cited by 1,329

USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2

Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,174

Novel Systemic Therapies for Advanced Gastric Cancer

Kim, H. J., & Oh, S. C. (2018) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2018.18.e3 · Cited by 45

Advances in Molecular and Clinical Subtyping of Breast Cancer and Their Implications for Therapy

Cadoo, K. A., Traina, T. A., & King, T. A. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.006 · Cited by 43

miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells

He, X.-H., Zhu, W., Yuan, P., Jiang, S., Li, D., Zhang, H.-W., & Liu, M.-F. (2016) · Oncogene · doi:10.1038/onc.2016.132 · Cited by 43

Overcoming Treatment Resistance in HER2-Positive Breast Cancer

Puglisi, F., Minisini, A. M., Angelis, C. D., & Arpino, G. (2012) · Drugs · doi:10.2165/11634000-000000000-00000 · Cited by 41

G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program

Mabe, N. W., Garcia, N. M. G., Wolery, S. E., Newcomb, R., Meingasner, R. C., Vilona, B. A., Lupo, R., Lin, C., Chi, J., & Alvarez, J. V. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108341 · Cited by 40

Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer

Almstedt, K., Krauthauser, L., Kappenberg, F., Wagner, D., Heimes, A.-S., Battista, M. J., Anić, K., Krajnak, S., Lebrecht, A., Schwab, R. M., et al. (2023) · Cancers · doi:10.3390/cancers15051413 · Cited by 41

Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer.

Branco, F., Machado, D. H., Silva, F. F., André, S., Catarino, A., Madureira, R., Moreira-Pinto, J., Godinho, J. P. B., Simões, P., Brito, M., et al. (2019) · PubMed Central · Cited by 39

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Gris‐Oliver, A., Palafox, M., Monserrat, L., Brasó‐Maristany, F., Òdena, A., Sánchez-Guixé, M., Ibrahim, Y. H., Villacampa, G. J., Grueso, J., Parés, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3324 · Cited by 39

Intrinsic Resistance to Chemotherapy in Breast Cancer

Moulder, S. (2010) · Women s Health · doi:10.2217/whe.10.60 · Cited by 39

Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer

Tarantino, P., Ajari, O. W., Graham, N., Vincuilla, J., Parker, T., Hughes, M. E., Tayob, N., Garrido-Castro, A. C., Morganti, S., King, T. A., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113920 · Cited by 40

Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis

Li, C., Fan, H., Xiang, Q., Xu, L., Zhang, Z., Liu, Q., Zhang, T., Ling, J., Zhou, Y. F., Zhao, X., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05421-7 · Cited by 38

The Need to Examine Metastatic Tissue at the Time of Progression of Breast Cancer: Is Re-biopsy a Necessity or a Luxury?

Khasraw, M., Brogi, E., & Seidman, A. D. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0137-9 · Cited by 37

Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo

Zoeller, J. J., Vagodny, A., Taneja, K. L., Tan, B. Y., O’Brien, N. A., Slamon, D. J., Sampath, D., Leverson, J. D., Bronson, R. T., Dillon, D. A. R., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0743 · Cited by 37

Developing PEGylated Reversed D‑Peptide as a Novel HER2-Targeted SPECT Imaging Probe for Breast Cancer Detection

Du, S., Luo, C., Yang, G., Gao, H., Wang, Y., Li, X., Zhao, H., Luo, Q., Ma, X., Shi, J., et al. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00334 · Cited by 37

Prognostic implications of receptor discordance between primary and recurrent breast cancer

Matsumoto, A., Jinno, H., Murata, T., Seki, T., Takahashi, M., Hayashida, T., Kameyama, K., & Kitagawa, Y. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0759-2 · Cited by 37

Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases

Zhu, S., Lu, Y., Fei, X., Shen, K., & Chen, X. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02403-x · Cited by 35

Antibody-lectin chimeras for glyco-immune checkpoint blockade

Stark, J. C., Gray, M. A., Ibarlucea-Benitez, I., Lustig, M., Bond, A., Cho, B., Govil, I., Luu, T., Priestley, M. J., Veth, T. S., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02884-6 · Cited by 41

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas

Martín-Castillo, B., López‐Bonet, E., Cuyàs, E., Viñas, G., Pernas, S., Dorca, J., & Menéndez, J. A. (2015) · Oncotarget · doi:10.18632/oncotarget.6094 · Cited by 35

An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs

Gandullo‐Sánchez, L., & Pandiella, A. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216024 · Cited by 32

Response to HER-2 Pulsed DC1 Vaccines is Predicted by Both HER-2 and Estrogen Receptor Expression in DCIS

Fracol, M. E., Xu, S., Mick, R., Fitzpatrick, E., Nisenbaum, H. L., Roses, R. E., Fisher, C. S., Tchou, J. C., Fox, K. R., Zhang, P., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3119-y · Cited by 34

Companion Diagnostics in Oncology - Current Status and Future Aspects

Jørgensen, J. T. (2013) · Oncology · doi:10.1159/000353454 · Cited by 34

Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy

Gonzalez-Angulo, A. M., Liu, S., Chen, H., Chávez‐MacGregor, M., Şahin, A. A., Hortobágyi, G. N., Mills, G. B., Do, K.-A., & Meric‐Bernstam, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds530 · Cited by 34

Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine

Goh, G., Schmid, R., Guiver, K., Arpornwirat, W., Chitapanarux, I., Ganju, V., Im, S., Kim, S., Dechaphunkul, A., Maneechavakajorn, J., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002136 · Cited by 34

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma

Peng, J., Zhang, X., Song, J., Liang, R., Luo, R., Li, H., & Wang, Y. (2019) · Medicine · doi:10.1097/md.0000000000013554 · Cited by 34

Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer

Kijima, T., Arigami, T., Uenosono, Y., Hiraki, T., Yanagita, S., Matsushita, D., Okubo, K., Shimonosono, M., Ishigami, S., Maemura, K., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13927 · Cited by 34

Single-cell RNA sequencing and bioinformatics as tools to decipher cancer heterogenicity and mechanisms of drug resistance

Rosati, D., & Giordano, A. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114811 · Cited by 36

Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue

Loria, R., Vici, P., Lisa, F. S. D., Soddu, S., Maugeri‐Saccà, M., & Bon, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877380 · Cited by 34

Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer

Zhao, F., Miyashita, M., Hattori, M., Yoshimatsu, T. F., Howard, F. M., Kaneva, K., Jones, R., Bell, J. S. K., Fleming, G. F., Jaskowiak, N. T., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.3329 · Cited by 33

Challenges and prospects in HER2-positive breast cancer-targeted therapy

Li, X., Zhang, X., Yin, S., & Nie, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104624 · Cited by 39

Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy

Li, X., Wang, M., Wang, M., Yu, X., Guo, J., Sun, T., Yao, L., Zhang, Q., & Xu, Y. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2019.22.e49 · Cited by 31

Pathology after neoadjuvant treatment – How to assess residual disease

Viale, G., & Fusco, N. (2021) · The Breast · doi:10.1016/j.breast.2021.11.009 · Cited by 31

Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy.

Hosking, M. P., Shirinbak, S., Omilusik, K., Chandra, S., Kaneko, M., Gentile, A., Yamamoto, S., Shrestha, B., Grant, J., Boyett, M., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.05.007 · Cited by 30

Signatures of Tumor–Immune Interactions as Biomarkers for Breast Cancer Prognosis

Manjili, M. H., Najarian, K., & Wang, X. (2012) · Future Oncology · doi:10.2217/fon.12.57 · Cited by 30

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

Tintelnot, J., Goekkurt, E., Binder, M., Thuss-Patience, P. C., Lorenzen, S., Knorrenschild, J. R., Kretzschmar, A., Ettrich, T. J., Lindig, U., Jacobasch, L., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06958-3 · Cited by 30

Targeting HER2 heterogeneity in early-stage breast cancer

Pernas, S., & Tolaney, S. M. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000685 · Cited by 31

Macroscopic handling and reporting of breast cancer specimens pre‐ and post‐neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches

Pinder, S. E., Rakha, E. A., Purdie, C. A., Bartlett, J. M. S., Francis, A., Stein, R. C., Thompson, A. M., & Shaaban, A. M. (2015) · Histopathology · doi:10.1111/his.12649 · Cited by 29

Current Approaches and Emerging Directions in HER2-resistant Breast Cancer

Brufsky, A. (2014) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s9453 · Cited by 29

Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy

Dong, Z., Huang, Z., Li, S., Wang, Y., Yao, Y., Yang, X., & Xu, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.021 · Cited by 30

Differences in the Receptor Status between Primary and Recurrent Breast Cancer - The Frequency of and the Reasons for Discordance

Heitz, F., Barinoff, J., du Bois, O., Hils, R., Fisseler‐Eckhoff, A., Harter, P., Heitz, J., Willenbrock, K., Traut, A., & du Bois, A. (2013) · Oncology · doi:10.1159/000346184 · Cited by 29

Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma

Chong, Q.-Y., You, M., Pandey, V., Banerjee, A., Chen, Y., Poh, H.-M., Zhang, M., Ma, L., Zhu, T., Basappa, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18431 · Cited by 28

Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors

Chica-Parrado, M. D. R., Godoy-Ortíz, A., Jiménez, B., Ribelles, N., Barragán, I., & Alba, E. (2020) · Cancers · doi:10.3390/cancers12082012 · Cited by 29

Recent developments in peptide-based SPECT radiopharmaceuticals for breast tumor targeting

Ahmadpour, S., & Hosseinimehr, S. J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116870 · Cited by 28

Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease

Dowling, G. P., Keelan, S., Cosgrove, N. S., Daly, G. R., Giblin, K., Toomey, S., Hennessy, B. T., & Hill, A. D. K. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07431-6 · Cited by 27

Latest biopsy approach for suspected metastases in patients with breast cancer

Niikura, N., Odisio, B. C., Tokuda, Y., Symmans, W. F., Hortobágyi, G. N., & Ueno, N. T. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.182 · Cited by 27

Influence of Neoadjuvant Chemotherapy on HER2/neu Status in Invasive Breast Cancer

Li, P., Liu, T., Wang, Y., Shao, S., Zhang, W., Lv, Y., Yi, J., & Wang, Z. (2012) · Clinical Breast Cancer · doi:10.1016/j.clbc.2012.09.011 · Cited by 27

Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer

Cockburn, A., Yan, J., Rahardja, D., Euhus, D., Peng, Y. S., Fang, Y. V., & Sarode, V. R. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.09.002 · Cited by 27

Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances

Mrkonjic, M., Berman, H. K., Done, S. J., Youngson, B. J., & Mulligan, A. M. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205598 · Cited by 26

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER 2 alterations

Torigoe, H., Shien, K., Takeda, T., Yoshioka, T., Namba, K., Sato, H., Suzawa, K., Yamamoto, H., Soh, J., Sakaguchi, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13571 · Cited by 25

HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models

Gameiro, A., Nascimento, C., Correia, J., & Ferreira, F. (2021) · Cancers · doi:10.3390/cancers13092007 · Cited by 28

Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer

Ahn, S., Kim, H. J., Kim, M., Chung, Y. R., Kang, E., Kim, E., Kim, S. H., Kim, Y. J., Kim, J. H., Kim, I. A., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.552 · Cited by 25

Texture Analysis of Breast DCE-MRI Based on Intratumoral Subregions for Predicting HER2 2+ Status

Lu, H., & Yin, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00543 · Cited by 24

Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1

Betts, A. M., Clark, T. H., Jasper, P., Tolsma, J., van der Graaf, P. H., Graziani, E. I., Rosfjord, E. C., Sung, M. S., Ma, D., & Barletta, F. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09702-3 · Cited by 24

Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience

Coiro, S., Gasparini, E., Falco, G., Santandrea, G., Foroni, M., Besutti, G., Iotti, V., Cicilia, R. D., Foroni, M., Mele, S., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11122249 · Cited by 24

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?

Ishimine, Y., Goto, A., Watanabe, Y., Yajima, H., Nakagaki, S., Yabana, T., Adachi, T., Kondo, Y., & Kasai, K. (2015) · Case Reports in Gastrointestinal Medicine · doi:10.1155/2015/132030 · Cited by 24

PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

Miller, T., & Arteaga, C. (2011) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2011.10.024 · Cited by 24

Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data

Patel, S. A., & DeMichele, A. M. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0613-6 · Cited by 22

Breast cancer, neoadjuvant chemotherapy and residual disease

Chávez‐MacGregor, M., & Gonzalez-Angulo, A. M. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0538-0 · Cited by 22

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates

Escrivá-de-Romaní, S., & Saura, C. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.52 · Cited by 22

Metastases to and from the Breast

Bombonati, A., & Lerwill, M. F. (2012) · Surgical pathology clinics · doi:10.1016/j.path.2012.06.004 · Cited by 21

Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy

Rossi, L., Verrico, M., Tomao, F., Ricci, F., Fontana, A., Spinelli, G. P., Colonna, M., Vici, P., & Tomao, F. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03981-5 · Cited by 21

In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non-water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines

Ghadban, T., Jessen, A., Reeh, M., Dibbern, J. L., Mahner, S., Müller, V., Wellner, U. F., Güngör, C., Izbicki, J. R., & Vashist, Y. K. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2696 · Cited by 20

The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review

Asgari-Karchekani, S., Aryannejad, A., Mousavi, S. A., Shahsavarhaghighi, S., & Tavangar, S. M. (2022) · Medical Oncology · doi:10.1007/s12032-022-01817-6 · Cited by 23

Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models

Yang, L., Bhattacharya, A., Peterson, D. L., Li, Y., Liu, X., Marangoni, E., Robila, V., & Zhang, Y. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101078 · Cited by 20

Resistance to Targeted Therapies in Breast Cancer

Braga, S. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3347-1_8 · Cited by 21

Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study

Chen, Y., Liu, X., Yu, K., Sun, X., Xu, S., Qiu, P., Lv, Z., Zhang, X., Guo, A., & Xu, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-6924 · Cited by 19

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease

Chan, A., Morey, A. L., Brown, B., Hastrich, D. J., Willsher, P. C., & Ingram, D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-555 · Cited by 19

The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients

Yuan, J., Ding, N., & Xiao, Z. Q. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.537265 · Cited by 19

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer

Allegretti, M., Fabi, A., Giordani, E., Ercolani, C., Romania, P., Nisticò, C., Gasparro, S., Barberi, V., Ciolina, M., Pescarmona, E. O., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01438-z · Cited by 19

Discordance of HER2 Expression and/or Amplification on Repeat Testing

DiPeri, T. P., Kong, K., Varadarajan, K., Karp, D. D., Ajani, J. A., Pant, S., Press, M. F., Piha-Paul, S. A., Dumbrava, E. E. I., & Meric‐Bernstam, F. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0630 · Cited by 18

Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic

Fabi, A., Mottolese, M., & Segatto, O. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1169-7 · Cited by 18

Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Relapsing Post-Adjuvant Trastuzumab: Pattern of Recurrence, Treatment and Outcome

Krell, J., James, C. R., Shah, D., Gojiš, O., Lim, A. K. P., Riddle, P., Ahmad, R., Makris, A., Cowdray, A., Chow, A., et al. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.03.012 · Cited by 18

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

Esteva, F. J., Franco, S. X., Hagan, M. K., Brewster, A. M., Somer, R. A., Williams, W., Florance, A. M., Turner, S., Stein, S., & Perez, A. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0129 · Cited by 18

Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer

Li, Z., Zhao, H., Hu, H., Shang, H.-L., Ren, Y., Qiu, W., Su, H., Lyu, H., & Chen, X. (2024) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2024.03.07 · Cited by 17

Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer

Gouda, M. A., Gonugunta, A. S., Dumbrava, E. E. I., Yap, T. A., Rodon, J. A., Piha-Paul, S. A., Pohlmann, P. R., Damodaran, S., Murthy, R. K., Valero, V., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3468 · Cited by 17

High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer to a Novel Nonanthracycline Neoadjuvant Chemotherapy

Zelnak, A. B., Nikolinakos, P. G., Srinivasiah, J., Jonas, W. S., Pippas, A. M., Liu, Y., Li, X., Torres, M. A., & O'Regan, R. M. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.06.004 · Cited by 17

Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers

Feng, Z., Wen, H., Ju, X., Bi, R., Chen, X., Yang, W., & Wu, X. (2017) · Oncotarget · doi:10.18632/oncotarget.15858 · Cited by 17

Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study

Ran, R., Zhao, S., Zhou, Y., Hang, X., Wang, H. Z., Fan, Y., Zhang, Y., Qiao, Y., Yang, J., & Dong, D. (2024) · BMC Cancer · doi:10.1186/s12885-024-12974-4 · Cited by 16

Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy

Tanaka, S., Luk, S. O., Kiyokawa, J., Onozato, M. L., Iafrate, A. J., Shah, K., Martuza, R. L., Rabkin, S. D., Batchelor, T. T., Cahill, D. P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37437-2 · Cited by 15

Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients

Lu, Y., Tong, Y., Chen, X., & Shen, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638619 · Cited by 16

A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting ( ICCR )

Bossuyt, V., Provenzano, E., Symmans, W. F., Webster, F., Allison, K. H., Dang, C. T., Gobbi, H., Kulka, J., Lakhani, S. R., Moriya, T., et al. (2024) · Histopathology · doi:10.1111/his.15165 · Cited by 16

Adjuvant Therapy Reduces the Benefit of Palliative Treatment in Disseminated Breast Cancer - Own Findings and Review of the Literature

Kleeberg, U. R., Fink, M. K., Tessen, H.-W., Nennecke, A., Hentschel, S., & Bartels, S. (2013) · Oncology Research and Treatment · doi:10.1159/000351253 · Cited by 16

New developments in the treatment of HER2-positive breast cancer

Nahta, R. (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s24976 · Cited by 16

Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges

Laokulrath, N., Gudi, M. A., Salahuddin, S. A., Chong, A. P. Y., Ding, C. S. L., Iqbal, J., Leow, W. Q., Tan, B. Y., Tse, G. M.-K., Rakha, E. A., et al. (2024) · Histopathology · doi:10.1111/his.15213 · Cited by 15

Pathological complete response in younger and older breast cancer patients

Kołacińska, A., Chałubińska, J., Błasińska-Morawiec, M., Dowgier-Witczak, I., Fendler, W. M., Kordek, R., & Morawiec, Z. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.28559 · Cited by 15

Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer

Mayer, E. L., Gropper, A. B., Harris, L. N., Gold, J. M., Parker, L. M., Kuter, I., Come, S. E., Najita, J., Guo, H., Winer, E. P., et al. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.07.010 · Cited by 15

Evaluation of hormone receptor, human epidermal growth factor receptor‐2 and K i‐67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patients

Ge, W., Yang, B., Wen-shu, Z., Zheng, G., Dai, Y., Han, C., Yang, L. H., & Zheng, M. (2014) · Thoracic Cancer · doi:10.1111/1759-7714.12133 · Cited by 14

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

NBRST Investigators Group, Beitsch, P. D., Whitworth, P. W., Baron, P. L., Pellicane, J. V., Treece, T., Yoder, E. B., & Gittleman, M. A. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5329-6 · Cited by 14

Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy

Mohan, S. C., Walcott‐Sapp, S., Lee, M. K., Srour, M. K., Kim, S., Amersi, F. F., Giuliano, A. E., & Chung, A. P. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09814-1 · Cited by 14

HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report.

Niu, J., Gelbspan, D., Weitz, D. J., Markman, M., & Quan, W. (2014) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.045 · Cited by 14

Pathology Considerations in Patients Treated with Neoadjuvant Chemotherapy

Sahoo, S., & Lester, S. C. (2012) · Surgical pathology clinics · doi:10.1016/j.path.2012.06.005 · Cited by 14

Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients

He, Y., Zhang, J., Chen, H., Zhou, Y., Hong, L., Ma, Y., Chen, N., Zhao, W., & Tong, Z. (2023) · Frontiers in Surgery · doi:10.3389/fsurg.2022.1037215 · Cited by 13

Modern therapies and iatrogenic changes in breast pathology

Provenzano, E., & Pinder, S. E. (2016) · Histopathology · doi:10.1111/his.13098 · Cited by 13

Validation of the CPS+EG and Neo-Bioscore staging systems after preoperative systemic therapy for breast cancer in a single center in China

Xu, L., Duan, X., Zhou, B., Liu, Y., Ye, J., Liu, Z., Ma, C., Zhang, H., Zhang, S., Zhang, L., et al. (2018) · The Breast · doi:10.1016/j.breast.2018.03.010 · Cited by 13

The neoadjuvant approach in breast cancer treatment: it is not just about chemotherapy anymore

Caudle, A. S., & Hunt, K. K. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e3283416477 · Cited by 13

Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer

Shu, S., Iimori, M., Nakanishi, R., Jogo, T., Saeki, H., Oki, E., & Maehara, Y. (2018) · In Vivo · doi:10.21873/invivo.11405 · Cited by 13

Current World Literature

(2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e3283432017 · Cited by 13

Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells

Gao, Y., Shelling, A. N., Nolan, E., Porter, D. J. T., Leung, E. Y., & Wu, Z. (2024) · Journal of Liposome Research · doi:10.1080/08982104.2024.2305866 · Cited by 12

Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases

Васильевич, К. В., Alshevskaya, A., & Sennikov, S. V. (2024) · Biomedicines · doi:10.3390/biomedicines12030699 · Cited by 13

Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients

Giordani, E., Allegretti, M., Sinibaldi, A., Michelotti, F., Ferretti, G., Ricciardi, E., Ziccheddu, G., Valenti, F., Martino, S. D., Ercolani, C., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03105-9 · Cited by 12

Discordance in receptor status between primary and metastatic breast cancer and overall survival: A single-center analysis

Mellouli, M., Graja, S., Kridis, W. B., Ayed, H. B., Makni, S., Triki, M., Charfi, S., Khanfir, A., Boudawara, T. S., & Kallel, R. (2022) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2022.152044 · Cited by 12

Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes

Wetzel, C. L., Sutton, T. L., Gardiner, S. K., Farinola, M. A., Johnson, N., & Garreau, J. R. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26646 · Cited by 15

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

Guiu, S., Gauthier, M., Coudert, B. P., Bonnetain, F., Favier, L., Ladoire, S., Tixier, H., Guiu, B., Penault-Llorca, F. M., Ettore, F., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605939 · Cited by 48

Pathologic Complete Response and Survival after Trastuzumab-Based Neoadjuvant Therapy According to the Level of HER2-Amplification.

Guiu, S., Liegard, M., Tixier, H., Guy, F., Fumoleau, P., Coudert, B. P., & Arnould, L. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-1089

Relationship between levels of HER-2 amplification and pathologic complete response to trastuzumab-based neoadjuvant treatment.

Masini, C., Bisagni, A., Falco, G., Bassano, C., Baldi, L., Bisagni, G., Moretti, G., Albini, A., Ferrari, G., Boni, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.e11605

Treatment of HER2+ breast cancer: a retrospective of disease prognosis with loss of HER2 amplification on residual disease after neoadjuvant treatment in a community hospital setting.

Uczkowski, D., Sekhri, A., Gupta, S., Gendler, L. S., Misiukiewicz, K. J., Levin, M. B., & Guerin, B. (2023) · PubMed Central · Cited by 4